Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xospata (gilteritinib) for Acute Myeloid Leukaemia with FLT3 Mutation

Drug Name

Xospata® (gilteritinib)

Developer

Astellas

Therapy Class

Tyrosine kinase inhibitor

Product Description

FMS-like tyrosine kinase 3 (FLT3) inhibitor

Current Indication

Acute myeloid leukaemia

Market Sector

Oncology

Development Status

Approved in the US and Japan
Expand

Go Top